The Use of Biorepair Peribioma Toothpaste and Mousse for Home Oral Care in Patients Undergoing Periodontal Therapy

Sponsor
University of Pavia (Other)
Overall Status
Completed
CT.gov ID
NCT04809831
Collaborator
(none)
40
1
2
7.4
5.4

Study Details

Study Description

Brief Summary

This is a split-mouth randomized clinical trial in which a new domiciliary oral care protocol with Biorepair Peribioma Toothpaste and Mousse is evaluated in periodontal patients.

Condition or Disease Intervention/Treatment Phase
  • Other: Domiciliary oral care with Biorepair Peribioma Toothpaste + Mousse
  • Other: Domiciliary oral care with Curasept Toothpaste (chlorhexidine 0,2%)
N/A

Detailed Description

This is a split-mouth randomized clinical trial that aims to suggest an innovative protocol for domiciliary oral care of periodontal patients. In details, home use of Biorepair Peribioma Toothpaste and Mousse is proposed as a support of professional hygiene sessions.

Patients that respond to the eligibility criteria and that sign the informed consent are recruited for periodontal therapy.The first professional hygiene session is performed at the baseline (T0); the following ones will be performed after 3 (T1) and 6 months (T2) from the baseline. In each session, periodontal indices of inflammation are detected; then, subgingival removal of plaque and tartar is performed, followed by glycine air-flow application in periodontal pockets. A microbiological test is perfomed in order to detect red and orange complex bacteria. At this time, patients are randomly allocated into two groups:

  • Trial Group: domiciliary oral hygiene with Biorepair Peribioma Toothpaste and Mousse twice a day until T2 session.

  • Control Group: home oral hygiene with Curasept Toothpaste (0,2% Chlorhexidine) twice a day until T2 session.

At the end of T1 and T2 professional session, a satisfaction survey about Peribioma Toothpaste and Mousse will ben given to the patients.

Study Design

Study Type:
Interventional
Actual Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
This is a study in which patients are divided into two groups: Trial Group: professional dental hygiene at T0, T1 and T2 + Biorepair Peribioma Toothpaste and Mousse for domiciliary oral care twice a day until T2; Control Group: professional dental hygiene at T0, T1 and T2 + Curasept Toothpaste with chlorhexidine 0,2% twice a day until T2.This is a study in which patients are divided into two groups:Trial Group: professional dental hygiene at T0, T1 and T2 + Biorepair Peribioma Toothpaste and Mousse for domiciliary oral care twice a day until T2; Control Group: professional dental hygiene at T0, T1 and T2 + Curasept Toothpaste with chlorhexidine 0,2% twice a day until T2.
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
A Comparison Between Biorepair Peribioma Toothpaste and Mousse Versus Chlorhexidine 0,2% Toothpaste (Curasept Trattamento Rigenerante) for Domiciliary Oral Care in Periodontal Patients.
Actual Study Start Date :
Mar 22, 2021
Actual Primary Completion Date :
Oct 29, 2021
Actual Study Completion Date :
Nov 3, 2021

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Trial Group - Biorepair Peribioma Toothpaste + Mousse

Domiciliary oral hygiene with Biorepair Peribioma Toothpaste in association with Peribioma Mousse twice a day until T2 session.

Other: Domiciliary oral care with Biorepair Peribioma Toothpaste + Mousse
Patients will use Biorepair Peribioma Toothpaste and Mousse for domiciliary oral hygiene twice a day until T2 session.

Active Comparator: Control Group - Curasept Toothpaste (chlorhexidine 0,2%)

Domiciliary oral care with Curasept Toothpaste (chlorhexidine 0,2%) twice a day until T2 session.

Other: Domiciliary oral care with Curasept Toothpaste (chlorhexidine 0,2%)
Patients will use Curasept Toothpaste (chlorhexidine 0,2%) for domiciliary oral hygiene twice a day until T2 session.

Outcome Measures

Primary Outcome Measures

  1. Change in BOP - Bleeding on Probing (percentage) [3 and 6 months.]

    Site-specific assessment of the presence or absence of gum bleeding after the insertion of the periodontal probe for the detection of PPD, detected on 6 sites. Percentage of sites with bleeding on probing determines the BOP%.

  2. Change in BS - Bleeding Score [3 and 6 months.]

    Scoring criteria: 0 = no bleeding; 1 = punctiform bleeding in the site of probing; 2 = slightly extended bleeding in the site of probing; 3 = bleeding in more than a half of gingival margin; 4 = gingival border fully covered by blood.

  3. Change in SBI - Sulculus Bleeding Index (Muhulemann and Son, 1781) [3 and 6 months.]

    Scoring criteria: 0 = healthy looking papillary and marginal gingiva, no bleeding on probing; 1 = healthy looking gingiva, with bleeding on probing; 2 = bleeding on probing, change in color, no edema; 3 = bleeding on probing, change in color, slight edema; 4 = bleeding on probing, change in color, obvious edema; 5 = spontaneous bleeding, change in color, marked edema.

  4. Change in GI - Gingival Index (Loe and Silness, 1963) [3 and 6 months.]

    Scoring criteria: 0 = normal gingiva. 1 = mild inflammation, edema and swelling; no bleeding. 2 = moderate inflammation with edema, swelling and bleeding on probing. 3 = severe inflammation with marked edema, redness tissues, ulceration and spontaneous bleeding.

  5. Change in PPD - Probing Pocket Depth [3 and 6 months.]

    Evaluation (in mm) of the depth of the gingival sulcus, through a millimeter periodontal probe; it is detected from the gingival margin to the bottom of the gingival sulcus or periodontal pocket, evaluated at 6 sites.

  6. Change in CAL - Clinical Attachment Loss [3 and 6 months.]

    Measurement (in mm) of the position of the gingival margin in relation to the cemento-enamel junction (CEJ).

  7. Change in Percentage of pathological sites [3 and 6 months.]

    Evaluation of the presence of pathological probes expressed as a percentage.

  8. Change in R - Gingival recession [3 and 6 months.]

    Distance (in mm) between the gingival margin and the amelo-cemental junction.

  9. Change in PI - Plaque Index (Silness and Löe, 1964) [3 and 6 months.]

    Scoring criteria: 0 = no plaque; 1 = thin plaque layer at the gingival margin, only detectable by scraping with a probe; 2 = moderate layer of plaque along the gingival margin; interdental spaces free, but plaque is visible to the naked eye; 3 = abundant plaque along the gingival margin; interdental spaces filled with plaque.

  10. Change in Evaluation of the total height of the adherent gingiva [3 and 6 months.]

    Evaluation (in mm) of the total height of adherent gingiva.

  11. Change in API - Approximal Plaque Index (Lange, 1986) [3 and 6 months.]

    Following application of disclosing, a simple yes/no decision is made concerning whether the interproximal surfaces are covered by plaque (+) or not (-). The proportion of plaque-covered interproximal spaces is expressed as a percentage. Usually, in a given quadrant the interproximal spaces are scored from only one aspect (i.e. from the facial - Q2 and Q4 - or from the oral aspect - Q1 and Q3).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Presence of periodontal disease according to the recent 2017 classification (2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions): severity grade II-III and complexity grade I-II.

  • Presence of bilateral periodontal probes, for at least one tooth per side up to 20 elements with pathologic probes).

  • Patients' good compliance

Exclusion Criteria:
  • Patients with cardiac pacemaker

  • Patients suffering from neurological disorders

  • Patients suffering from psychological disorders

  • Pregnant women

Contacts and Locations

Locations

Site City State Country Postal Code
1 Unit of Dental Hygiene - Section of Dentistry - Department of Clinical, Surgical, Diagnostic and Paediatrics - University of Pavia Pavia Lombardy Italy 27100

Sponsors and Collaborators

  • University of Pavia

Investigators

  • Principal Investigator: Andrea Scribante, DDS, PhD., University of Pavia

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Andrea Scribante, Research Resident, Principal Investigator, University of Pavia
ClinicalTrials.gov Identifier:
NCT04809831
Other Study ID Numbers:
  • 2021-PERIBIOMA
First Posted:
Mar 22, 2021
Last Update Posted:
Jan 13, 2022
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Andrea Scribante, Research Resident, Principal Investigator, University of Pavia
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 13, 2022